Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Chief Scientific Officer | February 18, 2022 | February 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date February 18, 2022 · Filed February 23, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2032-02-17 | Direct | 60,000 |
Reported balance
After 2022-02-18 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-02-18 · Grant · Acquired 60,000 · Balance 60,000 F1: The options vest over 48 substantially equal monthly installments starting 03/17/2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest over 48 substantially equal monthly installments starting 03/17/2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2022 Filed Feb 23, 2022 17:30 UTC Amendment | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000899243-22-007415 · doc4a.xml · derivative · entry 1 Kalled Susan · CIK 0001860504 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting 03/17/2022. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 18:55 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001171843-22-001208 · ownership.xml · derivative · entry 1 Kalled Susan · CIK 0001860504 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-02-16 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting 03/17/2022 Read SEC document |
| May 03, 2021 Filed May 5, 2021 15:03 UTC | Compass Therapeutics, Inc. NONE · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018319 · doc4.xml · derivative · entry 1 Kalled Susan · CIK 0001860504 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2031-05-03 F1 · derivative.exercise_date: 25% of this option vests on May 3, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.